Is There Still a Role for Chemotherapy in Bladder and Prostate Cancer - Maria De Santis

November 7, 2018

(Length of discussion: 21 minutes)

Maria De Santis and Alicia Morgans review the role of chemotherapy in genitourinary malignancies. This discussion evolves to appropriate patient selection, sharing clinical preference in dosing chemotherapy and their view of supportive care.

Maria De Santis is a medical oncologist and Chair of Section for Interdisciplinary Genito-Urinary Cancer Medicine at the Charité Medical University Hospital, Berlin, Germany. She has been Associate Professor of Medicine at Paracelsus Medizinische Privatuniversität in Salzburg, Austria, since 2008, and working as a senior consultant at the 3rd Medical Department – Center of Oncology and Hematology at Kaiser Franz Josef-Spital in Vienna for 18 years, where she has also lead the Genito-Urinary Oncology Service for 11 years. From 2015 until April 2018 she was appointed Associate Clinical Professor for Oncology at the University of Warwick, Coventry, and working clinically in genitourinary oncology at the Queen Elizabeth Hospital, Cancer Center, in Birmingham, UK. Also, she has been appointed Adjunct Professor at the Department of Urology at the Medical University of Vienna, Austria, in 2016.

Alicia Morgans, MD, MPH